ArticlePDF Available

Epigenetic Regulation of Osteogenic and Chondrogenic Differentiation of Mesenchymal Stem Cells in Culture


Abstract and Figures

Management of mesenchymal stem cells (MSCs) capabilities to differentiate into osteogenic and chondrogenic lineages would be of utmost importance for their future use in difficult to treat cases of destroyed bone and cartilage. Thus, an understanding of the epigenetic mechanisms as important modulators of stem cell differentiation might be useful. Epigenetic mechanism refers to a process that regulates heritable and long-lasting alterations in gene expression without changing the DNA sequence. Such stable changes would be mediated by several mechanisms including DNA methylation and histone modifications. The involvement of epigenetic mechanisms during MSC bone and cartilage differentiation has been investigated during the past decade. The purpose of this review is to cover outstanding research works that have attempted to ascertain the underlying epigenetic changes of the nuclear genome during in vitro differentiation of MSCs into bone and cartilage cell lineages. Understanding such genomic alterations may assist scientists to develop and recognize reagents that are able to efficiently promote this cellular differentiation. Before summarizing the progress on epigenetic regulation of MSC bone and cartilage differentiation, a brief description will be given regarding in vitro conditions that favor MSC osteocytic and chondrocytic differentiation and the main mechanisms responsible for epigenetic regulation of differentiation.
Content may be subject to copyright.
CELL JOURNAL(Yakhteh), Vol 15, No 1, Spring 2013 1
Review Article
Epigenetic Regulation of Osteogenic and Chondrogenic
Dierentiation of Mesenchymal Stem Cells in Culture
Mohamadreza Baghaban Eslaminejad, Ph.D.1*, Nesa Fani, M.Sc.1, Maryam Shahhoseini, Ph.D.2
1. Department of Stem Cells and Developmental Biology at Cell Science Research Center, Royan Institute for Stem Cell
Biology and Technology, ACECR, Tehran, Iran
2. Department of Genetics at Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine,
ACECR, Tehran, Iran
* Corresponding Address: P.O.Box: 16635-148, Department of Stem Cells and Developmental Biology at Cell Science
Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran
Received: 4/Mar/2012, Accepted: 9/Oct/2012
Management of mesenchymal stem cells (MSCs) capabilities to differentiate into osteo-
genic and chondrogenic lineages would be of utmost importance for their future use in
difcult to treat cases of destroyed bone and cartilage. Thus, an understanding of the
epigenetic mechanisms as important modulators of stem cell differentiation might be use-
ful. Epigenetic mechanism refers to a process that regulates heritable and long-lasting
alterations in gene expression without changing the DNA sequence. Such stable changes
would be mediated by several mechanisms including DNA methylation and histone modi-
cations. The involvement of epigenetic mechanisms during MSC bone and cartilage dif-
ferentiation has been investigated during the past decade. The purpose of this review is to
cover outstanding research works that have attempted to ascertain the underlying epige-
netic changes of the nuclear genome during in vitro differentiation of MSCs into bone and
cartilage cell lineages. Understanding such genomic alterations may assist scientists to
develop and recognize reagents that are able to efciently promote this cellular differentia-
tion. Before summarizing the progress on epigenetic regulation of MSC bone and cartilage
differentiation, a brief description will be given regarding in vitro conditions that favor MSC
osteocytic and chondrocytic differentiation and the main mechanisms responsible for epi-
genetic regulation of differentiation.
Keywords: Mesenchymal Stem Cells, Chondrogenesis, Osteogenesis, Epigenetic
Cell Journal(Yakhteh), Vol 15, No 1, Spring 2013, Pages: 1-10
Citation: Baghaban Eslaminejad MR, Fani N, Shahhoseini M. Epigenetic regulation of osteogenic and chondrogenic
differentiation of mesenchymal stem cells in culture. Cell J. 2013; 15(1): 1-10.
Although cells of multi cellular organisms are
genetically the same, their functions and structures
differ. This diversity is due to the differential ex-
pression of genes that originate during develop-
ment and can be retained through mitosis. Such
stable alteration in gene expression is called "epi-
genetic" since they are heritable in the short term
and do not involve the mutation of DNA itself (1).
During the adult life a similar mechanism (long-
lasting changes in gene expression) occurs during
progression from stem cells into differentiated
progenies. Differentiation of stem cells into spe-
cialized cells requires an up-regulation of genes
involved in creation of a specic cell phenotype
and suppression of genes responsible for cell
stemness (2). Epigenetic regulation of stem cell
differentiation refers to the functionally relevant
modications to the genome that do not involve
changes in nucleotide sequence. Examples of such
changes are DNA methylation and histone modi-
cations (Fig 1) that, in turn, act by modifying the
accessibility of genes to transcription factors and
other modulators (3, 4).
CELL JOURNAL(Yakhteh), Vol 15, No 1, Spring 2013 2
Epigenetic Regulation of MSC Differentiation
Fig 1: Two main epigenetic modications of a genome. A. DNA methylation (Me) and B. histone modications (4).
Mesenchymal stem cells (MSCs) are adult stem
cells that possess two major properties, self-re-
newal ability and the potential for multilineage
differentiation. Although MSC have been origi-
nally isolated from bone marrow, (5, 6) further
investigation has shown that multiple tissues con-
tain MSC-like populations (7-16). Reportedly, the
most important characteristics of MSCs are their
potential for differentiation into bone and cartilage
cell lineages (5, 6). This capacity has generated
tremendous excitement for the regeneration of
damaged bone and cartilage tissues that are either
incurable or difcult to cure due to insufciency
or failure of current therapies (17-20). Generally,
there two strategies for the application of MSCs
in regenerative medicine. One strategy uses cells
in an undifferentiated state, which allows them to
undergo differentiation atthe defective site. The
disadvantage of this strategy is the unwanted dif-
ferentiation of cells at the repair site. For instance,
if MSCs are to be used for the regeneration of
cartilage tissue, bone cells may be produced by
unwanted cell differentiation. An alternative ap-
proach is to fully differentiate MSCs into the de-
sired cells prior to their transplantation (21, 22).
With this strategy, the in vitro differentiation of
MSCs into bone and cartilage cell lineages seems
to be an inevitable step prior to their application in
the cell-based treatment of tissue defects. There-
fore, the differentiation process of MSCs must be
thoroughly understood, particularly in terms of its
regulatory mechanisms.
From the discovery of MSCs until now, numerous
attempts have been made to understand their differ-
entiation process. Particularly, research has focused
on differentiation into bone and cartilage cell lin-
eages the in vitro conditions favoring MSC bone
and cartilage differentiation. Furthermore, gene ex-
pression prole during progression from stem cell
into bone and cartilage cells are mostly revealed
(reviewed below). Another issue related to MSC
differentiation is the epigenetic regulation underly-
ing their osteocytic and chondrocytic differentiation
of which investigations have recently begun. The
purpose of this paper is to briey review the main
epigenetic mechanisms including DNA methylation
and histone modications, to summarize all studies
that have attempted to determine the underlying
epigenetic changes of the nuclear genome during
MSC bone and cartilage differentiation, and nally
to highlight the importance of epigenetic studies
in bone and cartilage engineering and regenerative
medicine. First, a brief description will be given re-
garding in vitro conditions necessary for osteocytic
and chondrocytic differentiation of MSCs and the
main transcription factors that promote tissue-spe-
cic gene expression during differentiation.
In vitro bone differentiation
In vitro bone differentiation of MSCs is a com-
plex process requiring multiple soluble inducers.
To establish an osteogenic culture, a conuent
CELL JOURNAL(Yakhteh), Vol 15, No 1, Spring 2013 3
Baghaban Eslaminejad et al.
monolayer culture of MSCs must be prepared and
provided with osteogenic medium, which typical-
ly consists of a basal medium such as Dulbecco’s
modied eagle medium (DMEM) supplemented
with osteogenic inducers. The most-frequently
used osteogenic supplement is composed of dexa-
methasone (10 nM), ascorbic acid (50µg/ml) and
ß-glycerol phosphate (10 mM). Dexamethasone is
the essential component; its continual supplemen-
tation is required for human MSC ostegenic differ-
entiation (23). Ascorbic acid, another osteogenic
component, is not essential for MSC bone differ-
entiation but its addition enhances production of
collagen-rich extracellular matrix (ECM) (24). ß-
glycerol phosphate in the osteogenic medium pro-
vides favorable conditions for culture mineraliza-
tion (25, 26).
In addition to the above mentioned frequent-
ly used reagents, other factors that impact MSC
differentiation into a bone cell lineage include 1,
25-dihydroxyvitamin D3 (27) and estrogen (28).
According to some studies parathyroid hormone
(PTH) exhibits an osteogenic effect on MSCs
if the culture is exposed intermittently to PTH
(29, 30). Local factors including prostagland
in,transforming growth factor-beta (TGF-β), -
broblast growth factor-2 (FGF-2) and bone mor-
phogenetic proteins (BMPs), particularly BMP6,
have been reported to promote in vitro MSC osteo-
genesis (31-33). Other factors which have osteo-
genic effects include lithium chloride (LiCl) and
6-bromoindirubin-3΄-oxim (BIO) (33). Addition-
ally, melatonin, a hormone secreted by the pineal
gland exhibits osteogenic effects on MSC culture
(34). The osteogenic factors thus far mentioned are
more effective when used synergistically. For ex-
ample, it has been shown that addition of BMP2
into a rat MSC culture enhanced the osteogenic
potency of FGF-2. Dexamethasone and vitamin
D3 as well as BMP2 and retinoic acid have been
shown to exhibit a synergistic effect on MSC os-
teogenic culture (35-37).
Osteogenic supplements of the MSC monolayer
culture eventually lead to expression of specic
osteoblastic transcription factors. Core binding
factor alpha 1 (Cbfa1), which is also called Runx2,
is one of the most studied transcription factors ex-
pressed in MSCs upon their commitment toward
an osteogenic differentiation (38, 39). Upon ex-
pression, Runx2 must be activated through post-
translational modications or protein-protein
interactions (40). Other transcription factors
may collaborate with Runx2 to promote os-
teogenic differentiation. It has been found that
TAZ, a transcriptional co-activator, co-activates
Runx2-dependent gene transcription in murine
MSCs (41). Runx2 activates the expression of
bone-related genes, including osteocalcin, col-
lagen I, osteopontin, bone sialo protein and the
parathormon receptor (PTHR) (39).
Osterix is another transcription factor whose in-
volvement has been discovered in MSC bone dif-
ferentiation. This discovery was particularly nota-
ble in murine MSCs transduced with the osterix
gene (42).
In vitro cartilage differentiation
The induction of chondrogenesis in MSCs de-
pends on the coordinated activities of two funda-
mental parameters: cell density and growth fac-
tors (43-46). The TGF-β super family of proteins
and their members, such as BMPs are established
regulatory factors in chondrogenesis. TGF-β pro-
motes proteoglycan deposition, so that in its ab-
sence the ECM of differentiated cells contains
modest amounts of proteoglycan (47). TGF-β1 is
a standard media additive used in cultures to in-
duce chondrogenesis. TGF-β3 has been shown to
induce a more rapid, representative expression of
a chondrogenic culture (48, 49). In the cell labora-
tory, cartilage differentiation of MSCs can be per-
formed in a pellet culture system. Approximately
2 × 105 cells (passages 2-3) must be condensed in
to a pellet by centrifugation at 300 g for 4 minutes,
followed by incubation in an atmosphere of 37˚C
and 5% CO2 in a 0.5 ml chondrogenic medium.
The chondrogenic medium should be composed
of 10 ng/ml TGF-ß3, 500 ng/ml BMP-6, 100 nM
dexamethasone, 50 µg/ml ascorbic 2-phosphate,
50 µg/ml ITS and 1.25 mg/ml bovine serum al-
bumin. Recently, we have shown that addition of
Lithium Chloride and a small molecule refereed
to as SB216763 can enhance glycoseaminogly-
cal deposition in the human marrow-derived MSC
chondrogenic culture (50).
Sox9 is the main transcription factor essential for
chondrocyte differentiation of MSCs. In the chon-
CELL JOURNAL(Yakhteh), Vol 15, No 1, Spring 2013 4
Epigenetic Regulation of MSC Differentiation
drogenic culture of MSCs. Expression of Sox9 is
followed by chondrocyte-specic gene expression
that includes collagen I and aggrecan. Genetic mu-
tations in Sox9 leads to congenital dwarsm syn-
drome (51).
Epigenetic mechanisms
DNA methylation
Currently, one of the epigenetic changes mostly
studied in mammals is DNA methylation, which
primarily involves the establishment of paren-
tal-specific imprinting during gametogenesis
(52). This process includes covalent binding
of a methyl group from a methyl donor, mainly
S-adenosylmethionine, to carbon 5 of the cyto-
sine that often is located in the CpG sites. This
enzymatic reaction is produced by a family of
enzymes called DNA methyltransferases (Dn-
mts) (53). There are several types of Dnmts, in-
cluding de novo Dnmt3a and Dnmt3b,which are
highly expressed in the developing mouse em-
bryo and promote global de novo methylation
after implantation (54). Dnmt1 is a methyltrans-
ferase that maintains the existing methylation
patterns upon cell division (52). Genomic re-
gions that contain a high number of methylated
cytosine are usually transcriptionally inactive.
The absence of DNA methylation is a prerequi-
site for transcriptionally active genes (55, 56).
Histone modications
Histones, the major structural proteins of chro-
mosomes, are small proteins that contain numer-
ous positively-charged amino acids such as lysine
and arginine. These positively charged amino acids
enable histones to tightly bind with the phosphate-
sugar backbone of double stranded DNA. These
proteins have a tail comprised of a long aminoacid
chain in their N-terminal domain that plays an im-
portant role in regulation of chromatin structure.
The histone tail domains are considered as master
control switches that dene the structural and func-
tional characteristics of chromatin at many lev-
els. These structures modulate DNA accessibility
within the nucleosome and are essential for stable
folding of oligonucleosome arrays into condensed
chromatin bers (57). Histone tails may have vary-
ing fates including acetylation, methylation, phos-
phorylation, polyadenylation, ribosylation, ubiqui-
tination and glycosylation. Combinations of these
modications determine the overall interaction of
histones with the DNA molecule, leading to acti-
vation and/or inhibition of transcription (58). Of
these, acetylation and methylation are the moste-
pigenetic mechanisms studied in transcriptional
Acetylation is one of the studied histone modica-
tions that occurs primarily at the lysine of histones
3 and 4, and is basically catalyzed by acetyltrans-
ferase enzymes such as HBO1, TIP60, MORF/Moz
and MOF. The consequence of this modication
is the loss of the positive charge of the lysine resi-
due which affects the histone’s binding to the DNA
molecule,and is dened as nucleosome opening
(Fig 2). Acetylation levels of histone tails depend-
ent on balance between the two enzymatic activities
of acetyltransferase and deacetylase (58). There are
four classes of histone deacetylase (HDAC). Class I
includes HDAC 1, 2, 3, and 4. Class II is comprised
of HDAC5, 6, 7, 9, and 10. Class III includes Sirtuin
1-7 and class IV includes HDAC11. Among these,
the HDAC of classes I, II and IV have the same se-
quences and structures. Sirtuin, however, has a dif-
ferent structure and a different catalytic mechanism.
Sirtuin proteins comprise a unique class of NAD ±
dependent protein deacetylases (59).
Fig 2: Histone acetylation and deactylation. Histone acetyl-
transferase (HATs) adds acetyl groups (Ac) onto histone
tails,which results in a nucleosome openingthus allowing
for transcription factors to access DNA and initiate gene
transcription.Histone deacetylases (HDACs) remove the Ac
from the histone tails, leading to a closed chromatin struc-
ture (61).
CELL JOURNAL(Yakhteh), Vol 15, No 1, Spring 2013 5
Baghaban Eslaminejad et al.
Acetylation of the histone tails leads to neu-
tralization of the partial electric charge of lysine
which in turn results in opening of the chromatin
structure. In vitro observation of this event is not
a simple task, but biophysical analysis has shown
that intranuclosomal linkages are important for
chromatin stabilization. According to research,
acetylation of lysine 9 on histone 3 has a dominant
negative effect on the formation of 30 nanometer
chromatin bers and higher-order structures (60).
Methylation is another histone modication that
plays different roles in epigenetic regulation of
gene expression. Histonemethylation usually oc-
curs on lysine and argenine residues (58). Among
these, methylation of lysines 4, 9, 27, 36, and 79 in
histone 3 and lysine 20 in histone 4 are dened in
transcriptional regulation. Methylation of lysines 9
and 27 of histone 3 (H3-K9, H3-K27) are present in
silent chromatin domains which are mainly related
to heterochromatin regions and inactive promot-
ers. In contrast, methylation of lysine 4 of histone
3 (H3-K4) which activates chromatin is primarily
observed in active promoters. If these two modi-
cations simultaneously occur in a promoter region,
the relevant gene goes to a poised state. This dual
epigenetic mark is observed in pluripotent cells
during development. The consequence of this "bi-
valent mark" is inactivation of the genes respon-
sible for specic cellular differentiation (62, 63).
Lysine can be mono-, di-or tri-methylated but ar-
gentine can be only mono-methylated.The level of
histone methylation is controlled by the dual enzy-
matic activities of methyl transferase and demeth-
ylase (64). Basically, there are two classes of pro-
teins that include thepolycomb group and tritorax
group complexes which act as methyl transferase
elements during development. These histone meth-
ylating enzymes encode methylation of lysine 27
and lysine 4 of histone 3, respectively. It has been
shown that a precise balance between these two
enzymatic activities modulates epigenetic regula-
tion of cellular differentiation processes (58).
Epigenetics of bone differentiation
Over the past decade, several researchers have
investigated epigenetic control of MSC bone dif-
ferentiation. In this context and according to nu-
merous research DNA methylation is dynamically
involved in the process of bone differentiation of
MSCs. For example, Villagra et al. have observed
a signicant hypermethylation at the osteocalcin
gene locus in undifferentiated cells, which was as-
sociated with the condensed chromatin structure.
Their subsequent examination has revealed that
during in vitro osteoblast differentiation, CpG
methylation of the osteocalcin promoter signi-
cantly decreased as the osteocalcin geneu pregu-
lated (65).
Arnsdorf et al. have designed a novel protocol to
promote MSC osteogenic differentiation by the ap-
plication of a mechanical stimulus. Following suc-
cessful differentiation they attempted to determine
the possible underlying mechanism of MSC osteo-
genesis. According to their results, the increase ob-
served in bone-specic gene expression was under
the control of epigenetic regulation of several os-
teogenic candidate genes. Mechanical stimulation
of MSCs reduced the DNA methylation state of the
genes, which lead to their increased expression (66).
Involvement of DNA methylation in osteogenic
differentiation of MSCs has also been reported by
Dansranjavin et al. (67). They demonstrated that
differentiation of MSCs into osteoblast and adi-
pocyte cells was accompanied by reduced expres-
sion of the stemness genes such as Brachyury and
LIN28, which basically occurred via hypermeth-
ylation of their promoter regions (67).
Hsiao et al. have observed epigenetic regula-
tion of the thyroid hormone receptor interactor 10
(Trip 10) during osteogenic induction of human
bone marrow-derived MSCs. To determine wheth-
er DNA methylation-induced gene silencing was
involved in this process, they applied an in vitro
method that specically methylated the Trip 10
promoter. The transfection of exogenous methyl-
ated Trip 10 promoter DNA into MSCs resulted in
progressive accumulation of methyl-cytosines at
the endogenous Trip 10 promoter, reduced Trip 10
expression, and accelerated MSC-to neuron and
MSC-to-osteocyte differentiation (68).
In contrast, Kang et al. have reported the lack
of a notable change in methylation levels of the
promoter region after in vitro osteocytic differen-
tiation of MSCs (69).
Histone acetylation is another epigenetic mecha-
nism reported to be involved in osteogenesis. Shen
et al. have investigated the chromatin-mediated
CELL JOURNAL(Yakhteh), Vol 15, No 1, Spring 2013 6
Epigenetic Regulation of MSC Differentiation
mechanisms by which the bone-specific osteo-
calcin gene is transcriptionally activated during
cessation of cell growth in ROS 17/2.8 osteosar-
coma cells, as well as during normal osteoblast
differentiation (70). They assayed acetylation of
histones H3 and H4 at the osteocalcin gene pro-
moter during and after cell proliferation by us-
ing the chromatin immunoprecipitation (ChIP)
technique. These researchers observed that both
the promoter and coding region of the osteoc-
alcin gene contained high levels of acetylated
H3 and H4 histones during the proliferative
period of osteoblast differentiation. According
to their findings active expression of the oste-
ocalcin gene in mature osteoblast and conflu-
ent ROS 17/2.8 cells is functionally linked to
preferential acetylation of core histones (70).
In contrast, Tan et al. have used microarrays to
investigate the roles of histone modifications
(H3K9Ac and H3K9Me2) upon the induction
of human MSC osteogenic differentiation. In
their research, enrichment of H3K9Acglobally
decreased at the gene promoters whereas the
number of promoters enriched with H3K9Me2
increased upon bone differentiation (71). We
have attributed the discrepancies in these two
reports to the difference in the cells (cell line
or MSCs) and the method (ChIP or microarray)
used in each experimental design.
Others, however in order to study the reverse role
of histone deacetylation in osteogenes is preferred
to measure the acetylation/deacetylation process.
Lee et al. examined the expression level of HDAC
and degree of histone acetylation at the promoter
regions of osteoblast genes. They have noted that
down-regulation of HDAC1 is an important pro-
cess for osteogenesis (72).
Histone methylation has also been reported as
an epigenetic mechanism underlying MSC oste-
ogenic differentiation. In this context Hassan et
al .have found that HOXA10 (a gene necessary
for embryonic patterning of skeletal elements)
contributes to osteogenic lineage determination
through activation of Runx2, alkaline phos-
phatase, osteocalcin and bone sialoprotein (73).
Their further investigations have revealed that
these effects are mediated through total chro-
matin hyperacetylation and H3K4 hypermeth-
ylation of the genes. In this context, Fan et al.
have found that the BCL-6 corepressor (BCOR)
mutation increases histone H3K4 and H3K36
methylation in MSCs. This, in turn, reactivates
transcription of the osteo-dentinogenic gene in
MSCs. In their study MSCs were isolated from a
patient with oculo-facio-cardio-dental (OFCD)
syndrome which is the result of a mutation in
the BCOR gene. This syndrome is characterized
by canine teeth with extremely long roots, con-
genital cataracts, craniofacial defects, and con-
genital heart disease (74).
Involvement of histone methylation in MSC
bone differentiation is also supported by the work
of Wei et al. These authors have found that the
activation of cyclin-dependent kinase 1 (CDK1)
promotes MSC bone differentiation through phos-
phorylization of theenhancer of the zeste homo-
logue 2 (EZH2) which is the catalaytic subunit of
the polycomb repressive complex 2 (PRC2) that
catalizes trimethylation of histone H3 on Lys 27
(H3K27) at Thr 487 (75).
Thus, according to the above-mentioned stud-
ies, several epigenetic regulations that include
DNA methylation, histone acetylation and
methylation might involve MSC osteogenic
differentiation. It is not clear whether all three
mechanisms are simultaneously involved dur-
ing MSC bone differentiation or if only one
mechanism promotes differentiation dependent
on the culture conditions. This issue needs ad-
ditional investigation.
Epigenetics of cartilage differentiation
Few studies have been conducted with regards
to epigenetic regulation of gene expression dur-
ing MSC cartilage differentiation. The work by
Ezura et al. (76) isnotable. These authors have in-
vestigated the CpG methylation status in human
synovium-derived MSCs during in vitro chondro-
genesis and found that DNA methylation levels of
CpG-rich promoters of chondrocyte-specic genes
were mostly maintained at low levels (76).
There are many investigations in which the epi-
genetic mechanism involved in cartilage differen-
tiation has been investigated by the use of chon-
drocyte or relevant cell lines. Histone acetylation
is among theepigenetic mechanisms that have
been reported to be involved in cartilage-specic
CELL JOURNAL(Yakhteh), Vol 15, No 1, Spring 2013 7
Baghaban Eslaminejad et al.
gene expression. In this context the role of p300,
an enzyme possessing a histone acetyltransferase
(HAT) activity, was observed in several studies.
Using the chondrosarcoma cell line SW1353,
Tsuda et al. have shown that Sox9 associates with
CREB-binding protein (CBP)/p300 via its car-
boxyl termini activation domain and functions as
an activator for cartilage tissue-specic gene ex-
pression during chondrocyte differentiation (77).
Later, Furumatsu et al. have investigated the mo-
lecular mechanism of synergy between Sox9 and
p300 in chromatin mediated transcription on chro-
matinized templates in vitro. Their results revealed
that p300 potentiated Sox9-dependent transcrip-
tion through hyperacetylation of histones. P300/
CBP acts as a coactivator to cartilage homeopro-
tein-1 (Cart1) through acetylation of the conserved
lysine residue adjacent to the homeodomain (78).
This point has been mentioned by Iioka et al. who
have conducted a study using an in vitro acetyla-
tion assaythat investigated the functional involve-
ment of p300/CBP during chondrogenesis. Cart1
is expressed selectively in chondrocyte lineage
during embryonic development (79).
Histone deacetylation by HDAC1 has been re-
ported to have a critical inhibitory role in cartilage
noncollagenous matrix deposition during cartilage
differentiation. Cartilage oligomeric matrix pro-
tein (COMP) is a noncollagenous matrix protein in
cartilage. In a study using Sox-9-null mice, Liu et
al. in 2007 have shown that the COMP gene was
inhibited by a transcription repressor,the negative
regulatory element (NRE)-binding protein by re-
cruiting HDAC1 to the COMP promoter (80). In
another study by the same authors on rat chon-
drosarcoma cells and BMP-2-treated C3H10T1/2
progenitor cells, it was observed that the leuke-
mia/lymphoma-related factor, a POZ domain-con-
taining transcriptional repressor, interacted with
HDAC1 and inhibited COMP gene expression and
chondrogenesis (81).
Using HDAC4-null mice, Vega et al. have found
that HDAC4 regulates chondrocyte hypertrophy
and endochondral bone formation by inhibiting the
activity of Runx2 which is a transcription factor
necessary for chondrocyte hypertrophy. It has been
shown that HDAC4-null mice display premature
ossication of developing bone; and conversely,
over expression of HDAC4 in proliferating chon-
drocytes in vivo inhibits chondrocyte hypertrophy
and differentiation (82).
In contrast to deacetylation, histone acetylation
favors cartilage differentiation which has been
shown in both in vivo and in vitro studies conduct-
ed by Hattori et al. These authors have conducted a
study to determine Sox9-regulated gene transcrip-
tion during chondrogenesis. In this study, they
have found a specic interaction between Sox9
and Tat interactive protein-60 (Tip60) which leads
to enhanced acetylation of Sox9, mainly through
the K61, 253, and 398 residues and subsequent en-
hancement of its transcriptional activity (83).
In some studies, results have shown that activity
of HDAC in cartilage differentiation is mediated
through the Wnt signaling pathway. In this context
Huh et al. have investigated the role of HDAC in
the expression of type II collagen that is a marker
of differentiated chondrocytes. They have found
that HDAC activity in a primary culture of articu-
lar cartilage decreased during dedifferentiation
that had been induced by serial monolayer culture;
the activity was recovered during 3-D culture. It
was also observed that HDAC inhibition promoted
the expression of Wnt-5a which is known to inhib-
it type II collagen expression. Conversely, knock-
down of Wnt-5a blocked the ability of HDAC in-
hibitors to suppress collagen II expression. They
have concluded that HDAC promotes collagen
II expression by suppressing the transcription of
Wnt-5a (84).
In conjunction and according to a study on MSCs,
during chondrogenic differentiation DNA methyla-
tion levels of CpG-rich promoters of the chondro-
cyte-specic genes are mostly maintained at low
levels. Conicting reports exist for non-MSCs, how-
ever numerous studies have reported an association
between histonehyperacetylation and chondrogenic
differentiation, (78, 79) or the inhibition of carti-
lage differentiation by histone deacetylation (80-83).
Some researchersbelieve that cartilage differentiation
is associated with histone deacetylation (84).For fur-
ther clarication of the subject, additional research
must be performed using MSCs.
Application of epigenetics in bone and cartilage
engineering and regeneration
The knowledge obtained by epigenetic studies
CELL JOURNAL(Yakhteh), Vol 15, No 1, Spring 2013 8
Epigenetic Regulation of MSC Differentiation
on MSC osteocytic/chondrocytic differentiation
could be applied to bone and cartilage engineering
as well as regenerative medicine. As mentioned
earlier, epigenetic modication is the process of
adding and removing chemical tags,i.e. acetyl or
methyl groups, on DNA or its surrounding his-
tones which results in activation or suppression of
the genes involved in stem cell differentiation. On
the other hand the key process in MSC-based bone
and cartilage engineering is to efciently direct the
cells into differentiated phenotypes within an ap-
propriated 3-D scaffold. After identication of epi-
genetic tags underlying MSC bone and cartilage
differentiation, the next step would be to locate
suitable chemicals or pharmaceuticals that are able
to promote those epigenetic modications. By us-
ing these reagents appropriate bone and cartilage
constructs could be developed. Such constructs
could be used for transplantation into large bone
and cartilage defects which are considered to be
problematic in the eld of orthopedics.
MSCs are considered as promising cell can-
didates for future treatment of difcult bone and
cartilage defects. Some scientists believe that
transplantation of MSCs at the differentiated state
would be more advantageous than transplantation
at the undifferentiated state. Thus, investigations
of MSC osteogenic and chondrogenic differentia-
tion are of utmost importance. One objective of
this research would be to dene the precise con-
dition under which MSC differentiation can occur
in a controlled, predictable manner. Understand-
ing epigenetic control of cell differentiation will
certainly enable scientists to achieve this goal. In
this context, promising progress has been made af-
ter approximately a decade of research. It has been
revealed that DNA methylation, as well as histone
acetylation and methylation are involved in MSC
bone differentiation.
In the context of cartilage differentiation of
MSCs, to the best of our knowledge, there are few
studies that have been performed. Most have been
conducted using chondrocytic cells or related cell
lines. According to these, predominantly DNA
methylation and histone acetylation are involved
in the control of cartilage differentiation. Under-
standing the epigenetic mechanism that regulates
cell differentiation may result in the development
of an appropriate reagent or enzyme that could
promote the necessary epigenetic changes of the
genome required for efcient differentiation of
MSCs. This, in turn, would be considered the pref-
erential cellular material with which to regenerate
large defects in bones and cartilages.
1. Jaenisch R, Bird A. Epigenetic regulation of gene expres-
sion: how the genome integrates intrinsic and environ-
mental signals. Nat Genet. 2003; 33 Suppl: 245-254.
2. Kouzarides T. Chromatin modications and their function.
Cell. 2007; 128(4): 693-705.
3. Vincent A, Van Seuningen I. Epigenetics, stem cells and
epithelial cell fate. Differentiation. 2009; 78(2-3): 99-107.
4. Qiu J. Epigenetics: unnished symphony. Nature. 2006;
441(7090): 143-145.
5. Friedenstein AJ, Chailakhjan RK, Lalykina KS. The de-
velopment of broblast colonies in monolayer cultures of
guinea-pig bone marrow and spleen cells. Cell Tissue Ki-
net. 1970; 3(4): 393-403.
6. Friedenstein AJ, Gorskaja JF, Kulagina NN. Fibroblast
precursors in normal and irradiated mouse hematopoietic
organs. Exp Hematol. 1976; 4(5): 267-274.
7. Fukumoto T, Sperling JW, Sanyal A, Fitzsimmons JS, Re-
inholz GG, Conover CA, et al. Combined effects of insulin-
like growth factor 1- and transforming growth factor-beta1
on periosteal mesenchymal stem cells during chondro-
genesis in vitro. Osteoarthritis Cartilage. 2003; 11(1): 55-
8. Noth U, Osyczka AM, Tuli R, Hickok NJ, Danielson KG,
Tuan RS. Multilineage mesenchymal differentiation poten-
tial of human trabecular bone-derived cells.J Orthop Res.
2002; 20(5): 1060-1069.
9. Eslaminejad MB, Mardpour S, Ebrahimi M. Mesenchymal
stem cells derived from rat epicardial versus epididymal
adipose tissue. Iran J Basic Med Sci. 2011; 14(1): 25-34.
10. Jankowsk RJ, Deasy BM, Huard J. Muscle-derived stem
cells. Gene Ther. 2002; 9(10): 642-647.
11. Eslaminejad MB, Vahabi S, Shariati M, Nazarian H. In vit-
ro growth and characterization of stem cells from human
dental pulp of deciduous versus permanent teeth. J Dent
(Tehran). 2010; 7(4): 185-195.
12. De bari C, Dell’Accio F, Tylzanowski P, Luyten FP. Multipo-
tent mesenchymal stem cells from adult human synovial
membrane. Arthritis Rheum. 2001; 44(8): 1928-1942.
13. Wan C, He Q, Li G. Allogenic peripheral blood derived
mesenchymal stem cells (MSCs) enhance bone regen-
eration in rabbit ulna critical-sized bone defect model. J
Orthop Res. 2006; 24(4): 610-618.
14. Eslaminejad MB, Jahangiri S, Aghdami N. Comparison
of proliferation, senescence and differentiation of murine
bone marrow-derived and amniotic uid mesenchymal
stem cells into skeletal cell lineages. Iran Red Cresent
Med J. 2010; 12(6): 608-616.
15. Fan X, Liu T, Liu Y, Ma X, Cui Z. Optimization of primary
culture condition for mesenchymal stem cells derived
from umbilical cord blood with factorial design. Biotechnol
Prog. 2009; 25(2): 499-507.
16. Eslaminejad MB, Taghiyar L. Mesenchymal stem cell puri-
cation from the articular cartilage cell culture. Iran J Basic
Med Sci. 2008; 10(3): 146-153.
17. Eslaminejad MB, Bagheri F. Tissue engineering approach
CELL JOURNAL(Yakhteh), Vol 15, No 1, Spring 2013 9
Baghaban Eslaminejad et al.
for reconstructing bone defects using mesenchymal stem
cells. Yakhteh. 2009; 11(3): 263-272.
18. Grässel S, Stöckl S, Jenei-Lanzl Z. Isolation, culture, and
osteogenic/chondrogenic differentiation of bone marrow-
derived mesenchymal stem cells. Methods Mol Biol. 2012;
879: 203-267.
19. Eslaminejad MB, Eftekhari-Yazdi P. Mesenchymal stem
cells: In vitro differentiation among bone and cartilage cell
lineages. Yakhteh. 2007; 9(3): 158-169.
20. Eslaminejad MB, Nikmahzar A, Piriea A. The structure of
Human Mesenchymal Stem Cells differentiated into car-
tilage in micro mass culture system. Yakhteh 2006, 8(3):
21. Pioletti DP, Montjovent MO, Zambelli PY, Applegate L.
Bone tissue engineering using foetal cell therapy. Swiss
Med Wkly. 2006 ; 136(35-36): 557-560.
22. Weissman IL. Translating stem and progenitor cell biol-
ogy to the clinic: barrier and opportunities. Science. 2000;
287(5457): 1442-1446.
23. Porter RM, Huckle WR, Goldstein AS. Effect of dexameth-
asone withdrawal on osteoblastic differentiation of bone
marrow stromal cells. J Cell Biochem. 2003; 90(1): 13-22.
24. Choi KM, Seo YK, Yoon HH, Song KY, Kwon SY, Lee
HS, et al. Effect of ascorbic acid on bone marrow-derived
mesenchymal stem cell proliferation and differentiation. J
Biosci Bioeng. 2008; 105(6): 586-594.
25. Chung CH, Golub EE, Forbes E, Tokuoka T, Shapiro IM.
Mechanism of action of beta-glycerophosphate on bone
cell mineralization. Calcif Tissue Int. 1992; 51(4): 305-311.
26. Coelho MJ, Fernandes MH. Human bone cell cultures in
biocompatibility testing. Part II: effect of ascorbic acid, be-
ta-glycerophosphate and dexamethasone on osteoblastic
differentiation. Biomaterials. 2000; 21(11): 1095-1102.
27. Rickard DJ, Kazhdan I, Leboy PS. Importance of 1,25-di-
hydroxyvitamin D3 and the nonadherent cells of marrow
for osteoblast differentiation from rat marrow stromal cells.
Bone. 1995; 16(6): 671-678.
28. Holzer G, Einhorn TA, Majeska RJ. Estrogen regulation of
growth and alkaline phosphatase expression by cultured
human bone marrow stromal cells. J Orthop Res. 2002;
20(2): 281-288.
29. Thomas T, Gori F, Khosla S, Jensen MD,Burguera B,
Riggs BL. Leptin acts on human marrow stromal cells to
enhance differentiation to osteoblasts and to inhibit dif-
ferentiation to adipocytes. Endocrinology. 1999; 140(4):
30. Nishida S, Yamaguchi A, Tanizawa T, Endo N, Mashiba
T, Uchiyama Y, et al. Increased bone formation by inter-
mittent parathyroid hormone administration is due to the
stimulation of proliferation and differentiation of osteopro-
genitor cells in bone marrow. Bone. 1994; 15(6): 717-723.
31. Maegawa N, Kawamura K, Hirose M, Yajima H, Takakura
Y, Ohgushi H. Enhancement of osteoblastic differentiation
of mesenchymal stromal cells cultured by selective com-
bination of bone morphogenetic protein-2 (BMP-2) and
broblast growth factor-2 (FGF-2). J Tissue Eng Regen
Med. 2007; 1(4): 306-313.
32. Massagué J, Wotton D. Transcriptional control by the
TGF-beta/Smad signaling system. EMBO J. 2000; 19(8):
33. Eslaminejad MB, Salami F, Soleimani M M, Abnousi M,
Eftekhari-Yazdi P. BIO treatment protects rat marrow-de-
rived mesenchymal stem cell culture against the TNF-α-
induced apoptosis. Yakhteh. 2009; 11(1): 35-42.
34. Radio NM, Doctor JS, Witt-Enderby PA. Melatonin en-
hances alkaline phosphatase activity in differentiating hu-
man adult mesenchymal stem cells grown in osteogenic
medium via MT2 melatonin receptors and the MEK/ERK
(1/2) signaling cascade. J Pineal Res. 2006; 40(4): 332-
35. Beresford JN, Joyner CJ, Devlin C, Triftt JT. The effects
of dexamethasone and 1,25-dihydroxyvitamin D3 on os-
teogenic differentiation of human marrow stromal cells in
vitro. Arch Oral Biol. 1994; 39(11): 941-947.
36. Rickard DJ, Kazhdan I, Leboy PS. Importance of 1,25-di-
hydroxyvitamin D3 and the nonadherent cells of marrow
for osteoblast differentiation from rat marrow stromal cells.
Bone. 1995; 16(6): 671-678.
37. Hanada K, Dennis JE, Caplan AI. Stimulatory effects of
basic broblast growth factor and bone morphogenetic
protein-2 on osteogenic differentiation of rat bone mar-
row-derived mesenchymal stem cells. J Bone Miner Res.
1997; 12(10): 1606-1614.
38. Yamaguchi A, Komori T, Suda T. Regulation of osteoblast
differentiation mediated by bone morphogenetic proteins,
hedgehogs, and Cbfa1. Endocr Rev. 2000; 21(4): 393-
39. Ducy P. Cbfa1: a molecular switch in osteoblast biology.
Dev Dyn. 2000; 219(4): 461-471.
40. Franceschi RT, Xiao G. Regulation of the osteoblast-spe-
cic transcription factor, Runx2: responsiveness to multi-
ple signal transduction pathways. J Cell Biochem. 2003;
88(3): 446-454.
41. Hong JH, Hwang ES, McManus MT, Amsterdam A, Tian
Y, Kalmukova R, et al. TAZ, a transcriptional modulator
of mesenchymal stem cell differentiation. Science. 2005;
309(5737): 1074-1078.
42. Tu Q, Valverde P, Chen J. Osterix enhances proliferation
and osteogenic potential of bone marrow stromal cells. Bi-
ochem Biophys Res Commun. 2006; 341(4): 1257-1265.
43. Johnstone B. Mesenchymal stem cells and chondrogen-
esis. Eur Cell Mater. 2002; 4 Suppl 1: 27.
44. Indrawattana N, Chen G, Tadokoro M, Shann LH, Ohgushi
H, Tateishi T, et al. Growth factor combination for chon-
drogenic induction from human mesenchymal stem cell.
Biochem Biophys Res Commun. 2004; 320(3): 914-919
45. Eslaminejad MB, Nikmahzar A, Thagiyar L,Nadri S, Mas-
sumi M. Murine mesenchymal stem cells isolated by low
density primary culture system. Develop Growth Differ.
2006; 48(6): 361-370.
46. Eslaminejad MB, Nikmahzar A, Piriea A. The structure of
Human Mesenchymal Stem Cells differentiated into carti-
lage in micro mass culture system. Yakhteh. 2006; 8(3):
47. Tapp H, Deepe R, Ingram JA, Kuremsky M, Hanley EN
Jr, Gruber HE. Adipose-derived mesenchymal stem cells
from the sand rat: transforming growth factor beta and 3D
co-culture with human disc cells stimulate proteoglycan
and collagen type I rich extracellular matrix. Arthritis Res
Ther. 2008; 10(4): R89.
48. Zhou S, Eid K, Glowacki J. Cooperation between TGF-
beta and Wnt pathways during chondrocyte and adipo-
cyte differentiation of human marrow stromal cells. J Bone
Miner Res. 2004; 19(3): 463-470.
49. Letamendia A, Labbé E, Attisano L. Transcriptional reg-
ulation by Smads: crosstalk between the TGF-beta and
Wnt pathways. J Bone Joint Surg Am. 2001; 83-A Suppl
1(pt 1): S31-39.
50. Eslaminejad MB, Karimi N, Shahhosseini M. Enhance-
ment of glycosaminoglycan-rich matrix production in
human marrow-derived mesenchymal stem cell chon-
drogenic culture by Lithium Chloride and SB216763 treat-
ment. Cell J. 2011; 13(2): 117-126.
51. Wagner T, Wirth J, Meyer J, Zabel B, Held M, Zimmer J, et
al. Autosomal sex reversal and campomelic dysplasia are
caused by mutations in and around the SRY-related gene
CELL JOURNAL(Yakhteh), Vol 15, No 1, Spring 2013 10
Epigenetic Regulation of MSC Differentiation
SOX9. Cell. 1994; 79(6): 1111-1120.
52. Li E. Chromatin modication and epigenetic reprogramming
in mammalian development. Nat Rev Genet. 2002 ;3(9):
53. Bird AP. CpG-rich islands and the function of DNA meth-
ylation. Nature. 1986; 321(6067): 209-213.
54. Okano M, Bell DW, Haber DA, Li E. DNA methyltrans-
ferases Dnmt3a and Dnmt3b are essential for de novo
methylation and mammalian development. Cell. 1999;
99(3): 247-257.
55. Bestor TH. DNA methylation: evolution of a bacterial im-
mune function into a regulator of gene expression and ge-
nome structure in higher eukaryotes. Philos Trans R Soc
Lond B Biol Sci. 1990; 326(1235), 179-187.
56. Bird AP. Functions for DNA methylation in vertebrates.
Cold Spring Harb Symp Quant Biol. 1993; 58:281-285.
57. Zheng C, Hayes JJ. Structures and interactions of the core
histone tail domains. Biopolymers. 2003; 68(4): 539-546.
58. Kouzarides T. Chromatin modications and their function.
Cell. 2007; 128(4): 693-705.
59. Villar-Garea A, Esteller M. Histone deacetylase inhibitors:
understanding a new wave of anticancer agents. Int J
Cancer. 2004; 112(2): 171-178.
60. Shogren-Knaak M, Ishii H, Sun JM, Pazin MJ, Davie JR,
Peterson CL. Histone H4-K16 acetylation controls chro-
matin structure and protein interactions. Science. 2006;
311(5762): 844-847.
61. Pons D, de Vries FR, van den Elsen PJ, Heijmans BT,
Quax PH, Jukema JW. Epigenetic histone acetylation
modiers in vascular remodelling: new targets for therapy
in cardiovascular disease. Eur Heart J. 2009; 30(3): 266-
62. Lunyak VV, Rosenfeld MG. Epigenetic regulation of stem
cell fate. Hum Mol Genet. 2008; 17(R1): R28-36.
63. Totonchi M, Shahhoseini M, Momeni Moghadam M, Ba-
harvand B. Epigenetics of stem cells. Yakhteh. 2008; 9(1):
64. Peterson CL, Laniel MA., Histones and histone modica-
tions. Curr Biol. 2004; 14(14): R546-551.
65. Villagra A, Gutiérrez J, Paredes R, Sierra J, Puchi M, Im-
schenetzky M, et al. Reduced CpG methylation is asso-
ciated with transcriptional activation of the bone-specic
rat osteocalcin gene in osteoblasts. J Cell Biochem. 2002;
85(1): 112-122.
66. Arnsdorf EJ, Tummala P, Castillo AB, Zhang F, Jacobs CR.
The epigenetic mechanism of mechanically induced osteo-
genic differentiation. J Biomech. 2010; 43(15): 2881-2886.
67. Dansranjavin T, Krehl S, Mueller T, Mueller LP, Schmoll
HJ, Dammann RH. The role of promoter CpG methylation
in the epigenetic control of stem cell related genes during
differentiation. Cell Cycle. 2009; 8(6): 916-924.
68. Hsiao SH, Lee KD, Hsu CC, Tseng MJ, Jin VX, Sun WS,
et al. DNA methylation of the Trip10 promoter accelerates
mesenchymal stem cell lineage determination. Biochem
Biophys Res Commun. 2010; 400(3): 305-312.
69. Kang MI, Kim HS, Jung YC, Kim YH, Hong SJ, Kim MK,
et al. Transitional CpG methylation between promoters
and retroelements of tissue-specic genes during human
mesenchymal cell differentiation. J Cell Biochem. 2007;
102(1): 224-239.
70. Shen J, Hovhannisyan H, Lian JB, Montecino MA, Stein
GS, Stein JL, et al. Transcriptional induction of the osteoc-
alcin gene during osteoblast differentiation involves acety-
lation of histones h3 and h4. Mol Endocrinol. 2003; 17(4):
71. Tan J, Lu J, Huang W, Dong Z, Kong C, Li L, et al. Genom-
ewide analysis of histone H3 lysine9 modications in hu-
man mesenchymal stem cell osteogenic differentiation.
PLoS One. 2009; 4(8): e6792.
72. Lee HW, Suh JH, Kim AY, Lee YS, Park SY, Kim JB. His-
tone deacetylase 1-mediated histone modication regu-
lates osteoblast differentiation. Mol Endocrinol. 2006;
20(10): 2432-2443.
73. Hassan MQ, Tare R, Lee SH, Mandeville M, Weiner B,
Montecino M, et al. HOXA10 controls osteoblastogene-
sis by directly activating bone regulatory and phenotypic
genes. Mol Cell Biol. 2007; 27(9): 3337-3352.
74. Fan Z, Yamaza T, Lee JS, Yu J, Wang S, Fan G, et al.
BCOR regulates mesenchymal stem cell function by epi-
genetic mechanisms. Nat Cell Biol. 2009; 11(8): 1002-
75. Wei Y, Chen YH, Li LY, Lang J, Yeh SP, Shi B, et al. CDK1-
dependent phosphorylation of EZH2 suppresses meth-
ylation of H3K27 and promotes osteogenic differentiation
of human mesenchymal stem cells. Nat Cell Biol. 2010;
13(1): 87-94.
76. Ezura Y, Sekiya I, Koga H, Muneta T, Noda M. Methyla-
tion status of CpG islands in the promoter regions of sig-
nature genes during chondrogenesis of human synovium-
derived mesenchymal stem cells. Arthritis Rheum. 2009;
60(5): 1416-1426.
77. Tsuda M, Takahashi S, Takahashi Y, Asahara H. Transcrip-
tional co-activators CREB-binding protein and p300 regu-
late chondrocyte-specic gene expression via association
with Sox9. J Biol Chem. 2003; 278(29): 27224-27229.
78. Furumatsu T, Tsuda M, Yoshida K, Taniguchi N, Ito T,
Hashimoto M, et al. Sox9 and p300 cooperatively regu-
late chromatin-mediated transcription. J Biol Chem. 2005;
280(42): 35203-35208.
79. Iioka T, Furukawa K, Yamaguchi A, Shindo H, Yamashita
S, Tsukazaki T. P300/CBP acts as a coactivator to car-
tilage homeoprotein-1 (Cart1), paired-like homeoprotein,
through acetylation of the conserved lysine residue adja-
cent to the homeodomain. J Bone Miner Res. 2003; 18(8):
80. Liu CJ, Zhang Y, Xu K, Parsons D, Alfonso D, Di Cesare
PE. Transcriptional activation of cartilage oligomeric matrix
protein by Sox9, Sox5, and Sox6 transcription factors and
CBP/p300 coactivators. Front Biosci. 2007; 12: 3899-3910.
81. Liu CJ, Prazak L, Fajardo M, Yu S, Tyagi N, Di Cesare
PE. Leukemia/lymphoma-related factor, a POZ domain-
containing transcriptional repressor, interacts with histone
deacetylase-1 and inhibits cartilage oligomeric matrix pro-
tein gene expression and chondrogenesis. J Biol Chem.
2004; 279(45): 47081-47091.
82. Vega RB, Matsuda K, Oh J, Barbosa AC, Yang X, Mead-
ows E, et al. Histone deacetylase 4 controls chondrocyte
hypertrophy during skeletogenesis. Cell. 2004; 119(4):
83. Hattori T, Coustry F, Stephens S, Eberspaecher H, Taki-
gawa M, Yasuda H, et al. Transcriptional regulation of
chondrogenesis by coactivator Tip60 via chromatin as-
sociation with Sox9 and Sox5. Nucleic Acids Res. 2008;
36(9): 3011-3024.
84. Huh YH, Ryu JH, Chun JS. Regulation of type II collagen
expression by histone deacetylase in articular chondro-
cytes. J Biol Chem. 2007; 282(23): 17123-17131.
... Histone deacetylases (HDACs) revert the process by removing the acetyl groups. (Modified from (Eslaminejad et al., 2013)). ...
Neurons have a highly specialized morphology whose signal-regulated remodeling is key to their function in neuronal networks. Activity-dependent nuclear calcium signaling is a crucial regulator of gene transcription in hippocampal and spinal cord neurons and mediates gene expression by directly acting on transcription factors or by regulating epigenetic processes, such as the induction of DNA methyltransferases (DNMTs) or the nucleo-cytoplasmic shuttling of class IIa histone deacetylases(HDAC4, -5, -7, and -9). Epigenetic mechanisms regulate several neuroadaptive phenomena in hippocampal neurons including, among others, synaptic plasticity and memory formation. In the first part of this thesis we describe how the subcellular localization of HDAC4 controls the morphology of hippocampal neurons by modulating the expression of a factor critical for dendrite architecture. Epigenetic regulators have also been suggested to mediate central sensitization in spinal cord neurons and the development of chronic pain. The transition from acute to chronic pain is considered a pathological manifestation of neuronal plasticity in nociceptive pathways and shares common molecular pathways with memory formation. However, if and how epigenetic gene regulatory events control also structural remodeling of spinal cord circuits, relevant for central sensitization, remains to be investigated. Here we characterized the impact of synaptic activity and chronic inflammatory pain on the expression and activity of DNMTs and HDACs in spinal cord neurons and found that the de novo methyltransferase Dnmt3a2 and HDAC4 were particularly affected. We demonstrate that activity-induced levels of Dnmt3a2 contribute to spinal sensitization and hypersensitivity in the CFA model of inflammatory pain by regulating the expression of pain- and plasticity-related genes. Moreover, we found that long-lasting, but not acute inflammatory pain, results in a nuclear export of HDAC4 in spinal cord neurons, which is accompanied by increased levels of histone 3 acetylation. Using recombinant adeno-associated virus-mediated expression of a nuclear localized dominant active mutant of HDAC4 in dorsal horn neurons, we demonstrated that nuclear HDAC4 blunts the development of mechanical hypersensitivity without affecting acute nociception. Next generation RNA-sequencing analysis produced a list of HDAC4-regulated candidate genes in the context of chronic inflammatory pain. The identified candidates include both well-known and novel mediators of chronic pain development and have been functionally tested in vivo with gain of function and loss of function experiments. Our results identify HDAC4 and its target genes, as key epigenetic regulators of central sensitization in chronic inflammatory pain and as possible targets for pain therapies.
... 18 In addition, epigenetic mechanisms, through the DNA modifying enzymes DNMTs and Ten-Eleven-Translocation (TETs), play an important role in the transcriptional control of genes related to both maintenance of pluripotentiality 19,20 and osteogenic potential. 21,22 Thus, the objective of this study was to determine the impact of the individual epigenetic and transcriptional profiles on the osteogenic potential of PDLCs, evaluating DNA methylation as a mechanism of transcriptional control. ...
Background: Mesenchymal cells' biology has been an important investigative tool to maximize bone regeneration through tissue engineering. Here we used mesenchymal cells from periodontal ligament (PDLCs) with high (h-) and low (l-) osteogenic potential, isolated from different donors, to investigate the impact of the individual epigenetic and transcriptional profiles on the osteogenic potential. Materials and methods: Genome-wide and gene-specific DNA (hydroxy)methylation, mRNA expression and immunofluorescence analysis were carried out in h- and l-PDLCs at DMEM (non-induced to osteogenesis) and OM (induced - 3rd and 10th days of osteogenic differentiation) groups in vitro. Results: Genome-wide results showed distinct epigenetic profile among PDLCs with most of the differences on 10th day of OM; DMEMs showed higher concentrations (xOM) of differentially methylated probes in gene body, intronic and open sea (3rd day), increasing this concentration in TSS200 and island regions, at 10 days. At basal levels, h- and l-PDLCs showed different transcriptional profiles; l-PDLCs demonstrated higher levels of NANOG/OCT4/SOX2, BAPX1, DNMT3A, TET1/3 and lower levels of RUNX2 transcripts, confirmed by NANOG/OCT4 and RUNX2 immunofluorescence. After osteogenic induction, the distinct transcriptional profile of multipotentiality genes was maintained among PDLCs. In l-PDLCs, the anti-correlation between DNA methylation and gene expression in RUNX2 and NANOG indicates methylation could play a role in modulating both transcripts. Conclusions: Epigenetic and transcriptional distinct profiles detected at basal levels among PDLCs were maintained after osteogenic induction. We cannot discard the existence of a complex that represses osteogenesis, suggesting the individual donors' characteristics have significant impact on the osteogenic phenotype acquisition. This article is protected by copyright. All rights reserved.
... Scaffold enhancement has become a widespread method to incorporate different factors that can more fully mimic the physiological function and architecture of bone tissue. Given the promise of EVs in therapeutic applications, it is important to recognize the epigenetic roots that underlie bone and cartilage degeneration (Van Meurs et al., 2019) and the potential use of chemicals and pharmaceuticals to promote the desired epigenetic modifications that drive chondrogenic and osteogenic differentiation in scaffolds (Eslaminejad et al., 2013). Indeed, EVs have potential to serve as vehicles for drug and molecule delivery to support skeletal tissue regeneration. ...
... Histone acetylation on lysine residues is tightly regulated by opposing actions of two families of enzymes, histone acetyltransferases (HATs) and histone deacetylases (HDACs) [40]. Hyperacetylation of histone tails induced by HATs results in an open chromatin formation that usually correlates with gene activation, whereas deacetylation by HDACs mediate a closed chromatin conformation and transcriptional suppression [41]. To further explore the presence of post-translational histone modifications in the regressing interdigits, we analyzed the expression of HDACs genes in the developing autopod by in situ hybridization (Figure 3). ...
Full-text available
During limb formation in vertebrates with free digits, the interdigital mesoderm is eliminated by a massive degeneration process that involves apoptosis and cell senescence. The degradation process is preceded by intense DNA damage in zones located close to methylated DNA, accompanied by the activation of the DNA repair response. In this study, we show that trimethylated histone 3 (H3K4me3, H3K9me3, and H3K27me3) overlaps with zones positive for 5mC in the nuclei of interdigital cells. This pattern contrasts with the widespread distribution of acetylated histones (H3K9ac and H4ac) and the histone variant H3.3 throughout the nucleoplasm. Consistent with the intense labeling of acetylated histones, the histone deacetylase genes Hdac1, Hdac2, Hdac3, and Hdac8, and at a more reduced level, Hdac10, are expressed in the interdigits. Furthermore, local treatments with the histone deacetylase inhibitor trichostatin A, which promotes an open chromatin state, induces massive cell death and transcriptional changes reminiscent of, but preceding, the physiological process of interdigit remodeling. Together, these findings suggest that the epigenetic profile of the interdigital mesoderm contributes to the sensitivity to DNA damage that precedes apoptosis during tissue regression.
... hBMSCs are typical adult MSCs with self-renew capabilities and can differentiate into osteoblasts, which may be a potential cell source for bone tissue engineering 30 . The osteogenic differentiation of hBMSCs is vital for the application for bone regeneration 31 . Therefore, it is important to study the molecular mechanisms that control hBMSCs osteogenic differentiation. ...
Full-text available
Osteoporosis is the most prevailing primary bone disease and a growing health care burden. The aim of this study was to clarify the functional roles and mechanisms of the circ-ITCH regulating osteogenic differentiation of osteoporosis. Circ-ITCH and yes-associated protein 1 (YAP1) levels were downregulated, but the miR‐214 level was upregulated in osteoporotic mice and patients. Knockdown of circ-ITCH inhibited the alkaline phosphatase (ALP) activity, mineralized nodule formation, and expression of runt-related transcription factor 2 (RUNX2), osteopontin (OPN), and osteocalcin (OCN) during osteogenic induction. Furthermore, miR-214 was a target of circ-ITCH, knockdown of miR-214 could impede the regulatory effects of sh-circ-ITCH on osteogenic differentiation. Moreover, miR-214 suppressed hBMSCs osteogenic differentiation by downregulating YAP1. Finally, in vivo experiments indicated that overexpression of circ-ITCH could improve osteogenesis in ovariectomized mice. In conclusion, circ-ITCH upregulated YAP1 expression to promote osteogenic differentiation in osteoporosis via sponging miR-214. Circ-ITCH could act as a novel therapeutic target for osteoporosis.
... These changes are often controlled by epigenetic mechanisms and require chromatin modification at the genes undergoing regulation (Yeo et al., 2007;Barrand and Collas, 2010;Fu et al., 2016). In addition to histone modifications and chromatin remodeling, DNA methylation (5-methylcytosine [5mC]) contributes to the control of the transcription factors' accessibility to regulatory elements (Vincent and Van Seuningen, 2009;Wiench et al., 2011;Eslaminejad et al., 2013). 5mC deposition is catalyzed by DNA methyltransferases (DNMTs); in addition, Ten Eleven Translocation (TET) enzymes promote the oxidation of 5mC, converting it to 5-hydroxymethylcytosine (5hmC), an intermediary in the process of active DNA demethylation (Tahiliani et al., 2009). ...
Full-text available
Periodontal ligament cells (PDLCs) have well documented osteogenic potential; however, this commitment can be highly heterogenous, limiting their applications in tissue regeneration. In this study, we use PDLC populations characterized by high and low osteogenic potential (h-PDLCs and l-PDLCs, respectively) to identify possible sources of such heterogeneity and to investigate whether the osteogenic differentiation can be enhanced by epigenetic modulation. In h-PDLCs, low basal expression levels of pluripotency markers (NANOG, OCT4), DNA methyltransferases (DNMT1, DNMT3B), and enzymes involved in active DNA demethylation (TET1, TET3) were prerequisite to high osteogenic potential. Furthermore, these genes were downregulated upon early osteogenesis, possibly allowing for the increase in expression of the key osteogenic transcription factors, Runt-related transcription factor 2 (RUNX2) and SP7, and ultimately, mineral nodule formation. l-PDLCs appeared locked in the multipotent state and this was further enhanced upon early osteogenic stimulation, correlating with low RUNX2 expression and impaired mineralization. Further upregulation of DNMTs was also evident, while pretreatment with RG108, the DNMTs' inhibitor, enhanced the osteogenic program in l-PDLCs through downregulation of DNMTs, increased RUNX2 expression and nuclear localization, accelerated expression of osteogenic markers, and increased mineralization. These findings point toward the role of DNMTs and Ten Eleven Translocations (TETs) in osteogenic commitment and support application of epigenetic approaches to modulate biomineralization in PDLCs.
... Normal or high expression of HDAC11 activity can directly enhance the immune response, and inhibition of HDAC11 will upregulate IL-10 expression and affect the process of metabolic inflammation (Villagra et al., 2009). Obesity coexists with low-level chronic inflammation in metabolic tissues (Laimer et al., 2002;Panagiotakos et al., 2005;Ramos-Nino, 2013;Xu et al., 2003). Inflammation is a key bridge between obesity and type II diabetes (Dalmas et al., 2014;Dandona et al., 2004). ...
Full-text available
At present, metabolic diseases, such as obesity and diabetes, have become the world's top health threats. These diseases are closely related to the abnormal development and function of adipocytes and metabolic inflammation associated with obesity. Histone deacetylase 11 (HDAC11), with a relatively unique structure and function in the HDAC family, plays a vital role in regulating cell growth, migration, and cell death. Currently, research on new key regulatory functions of HDAC11 in metabolic homeostasis is receiving more and more attention, and HDAC11 has also become a potential therapeutic target in the treatment of obesity and obesity‐related diseases. Here, we summarized the latest literature on the role of HDAC11 in regulating the progress of obesity‐related metabolic disorders.
... Using an assay based on dilution of a mitochondrially targeted photoactivatable green fluorescent protein, Forni et al. (2016) observed that chondrogenic MSCs undergo fewer fusion events than both undifferentiated MSCs and MSCs differentiated under osteo-and adipogenic conditions. Further support for the importance of mitochondrial remodeling comes from overexpression of a dominant negative Drp1, which resulted in a reduced ability to induce mitochondrial fragmentation and decreased expression of Col2a and Sox9, two genes important for cartilage formation (Hirao et al., 2006;Eslaminejad et al., 2013;Forni et al., 2016). This suggests that reorganization of the mitochondrial network toward a fragmented spherical phenotype plays an active role in commitment of MSCs to the chondrocyte lineage. ...
Full-text available
Mesenchymal stromal cell (MSC) metabolism plays a crucial role in the surrounding microenvironment in both normal physiology and pathological conditions. While MSCs predominantly utilize glycolysis in their native hypoxic niche within the bone marrow, new evidence reveals the importance of upregulation in mitochondrial activity in MSC function and differentiation. Mitochondria and mitochondrial regulators such as sirtuins play key roles in MSC homeostasis and differentiation into mature lineages of the bone and hematopoietic niche, including osteoblasts and adipocytes. The metabolic state of MSCs represents a fine balance between the intrinsic needs of the cellular state and constraints imposed by extrinsic conditions. In the context of injury and inflammation, MSCs respond to reactive oxygen species (ROS) and damage-associated molecular patterns (DAMPs), such as damaged mitochondria and mitochondrial products, by donation of their mitochondria to injured cells. Through intercellular mitochondria trafficking, modulation of ROS, and modification of nutrient utilization, endogenous MSCs and MSC therapies are believed to exert protective effects by regulation of cellular metabolism in injured tissues. Similarly, these same mechanisms can be hijacked in malignancy whereby transfer of mitochondria and/or mitochondrial DNA (mtDNA) to cancer cells increases mitochondrial content and enhances oxidative phosphorylation (OXPHOS) to favor proliferation and invasion. The role of MSCs in tumor initiation, growth, and resistance to treatment is debated, but their ability to modify cancer cell metabolism and the metabolic environment suggests that MSCs are centrally poised to alter malignancy. In this review, we describe emerging evidence for adaptations in MSC bioenergetics that orchestrate developmental fate decisions and contribute to cancer progression. We discuss evidence and potential strategies for therapeutic targeting of MSC mitochondria in regenerative medicine and tissue repair. Lastly, we highlight recent progress in understanding the contribution of Mohammadalipour et al. Mitochondrial Regulators of MSC Function MSCs to metabolic reprogramming of malignancies and how these alterations can promote immunosuppression and chemoresistance. Better understanding the role of metabolic reprogramming by MSCs in tissue repair and cancer progression promises to broaden treatment options in regenerative medicine and clinical oncology.
... MSCs are of tremendous interest to stem cell-based transplantation therapy; newly emerging research has implicated the important role of epigenetic mechanisms in regulating mesodermal lineage determination and differentiation. Evidence indicates that the induction of MSC differentiation toward osteoblasts is supported by epigenetic regulations [114]. ...
Full-text available
Efficient osteogenic differentiation of mesenchymal stem cells (MSCs) is a critical step in the treatment of bone defects and skeletal disorders, which present challenges for cell-based therapy and regenerative medicine. Thus, it is necessary to understand the regulatory agents involved in osteogenesis. Epigenetic mechanisms are considered to be the primary mediators that regulate gene expression during MSC differentiation. In recent years, epigenetic enzyme inhibitors have been used as epidrugs in cancer therapy. A number of studies mentioned the role of epigenetic inhibitors in the regulation of gene expression patterns related to osteogenic differentiation. This review attempts to provide an overview of the key regulatory agents of osteogenesis: transcription factors, signaling pathways, and, especially, epigenetic mechanisms. In addition, we propose to introduce epigenetic enzyme inhibitors (epidrugs) and their applications as future therapeutic approaches for bone defect regeneration
Mesenchymal stem cells are candidates for therapeutic strategies in periodontal repair due to their osteogenic potential. In this study, we identified epigenetic markers during osteogenic differentiation, taking advantage of the individual pattern of mesenchymal cells of the periodontal ligament with high (h-PDLCs) and low (l-PDLCs) osteogenic capacity. We found that the involvement of non-coding RNAs in the regulation of the RUNX2 gene is strongly associated with high osteogenic potential. Moreover, we evaluated miRs and genes that encode enzymes to process miRs and their biogenesis. Our data show the high expression of the XPO5 gene, and miRs 7 and 22 observed in the l-PDLCs might be involved in acquiring osteogenic potential, suppressing RUNX2 gene expression. Further, an inversely proportional correlation between lncRNAs (HOTAIR and HOTTIP) and RUNX2 gene expression was observed in both l- and h-PDLCs, and it was also related to the distinct osteogenic phenotypes. Thus, our results indicate the low expression of XPO5 in h-PDLC might be the limiting point for blocking the miRs biogenesis, allowing the high gene expression of RUNX2. In accordance, the low expression of miRs, HOTAIR, and HOTTIP could be a prerequisite for increased osteogenic potential in h-PDLCs. These results will help us to better understand the underlying mechanisms of osteogenesis, considering the heterogeneity in the osteogenic potential of PDLCs that might be related to a distinct transcriptional profile of lncRNAs and the biogenesis machinery.
Full-text available
The capacity of mesenchymal stem cells (WISCs) to differentiate among skeletal cell lineages and to undergo extensive proliferation in vitro renders them an appropriate source for cell-replacement therapy to heal defects of bone and cartilage tissue.It is argued that in bone and cartilage defects, MSCs would better be transplanted as fully-differentiated cells otherwise they may produce non-specific cells in defect sites. This notion may emphasize the importance of the studies considering in vitro bone and cartilage differentiation of MSCs. Indeed, the capacity of producing osteoblastic and chondrocytic cell lineage is among the earliest differentiation potentials of MSCs, being reported at first isolation of the cells. Recent studies, however indicate that MSCs could differentiate into more cell lineages than expected. The present study provides evidence for, in vitro potential of MSCs to differentiate into bone and cartilage cell lineages. As an introduction to the differentiation, the characteristics of MSCs have been described and MSCs differentiation reviewed. The culture condition for bone and cartilage differentiation, molecular regulation of the differentiation, signaling pathway involved during the differentiation, and the genes up-regulated upon bone and cartilage differentiation have also been described.
Full-text available
Objective Articular cartilage as an avascular skeletal tissue possesses limited capacity to heal. On the other hand, it is believed that the regeneration capacity of each tissue is largely related to its stem cell contents. Little is known about the presence of mesenchymal stem cells in articular cartilage tissue. This subject is investigated in the present study. Materials and Methods Articular cartilage was obtained from rats of Wistar strain and subjected to enzymatic digestion using 1:1 ratio of 0.2% collagenase I and 0.1% pronase. The released cells were then collected and cultivated in 25 cm2 culture flask, which was resulted in the appearance of two morphologically distinct cell populations. Fibroblastic population were purified and expanded through several subcultures, using their loose adherence on culture surfaces and examined in terms of differentiation potential. Results The primary culture mainly contained polygonal cells with few fibroblastic cells among them. Upon the first subculture, the fibroblastic cells appeared as aggregates of few cells among the polygonal cartilage cells. It was found that the fibroblastic cell population could easily detach from the culture surface following to a brief exposure to tripsin solution. Using this property, these cells purified and expanded by several subcultures. According to the results, the isolated cells were able to easily differentiate into chondrocytic, osteocytic and adipocytic cell lineages. Conclusion It seems that articular cartilage contains a distinct fibroblastic cell population with mesenchymal stem cell nature. These cells can be purified and expanded by cell culture methods, thanks to their loose adherence on the culture dish surfaces.
Full-text available
Cartilage mass produced from mesenchymal stem cell (MSC) differentiation would be a suitable candidate for use in regenerative medicine. Since the proper function of cartilage tissue is largely dependent on matrix glycosaminoglycan (GAG) contents, the objective of this study was to investigate the enhancing effect of two GSK3 inhibitors on the GAG content of cartilage produced by human marrow MSCs in vitro chondrogenesis. MSCs that were used in this experimental study were derived from human marrow aspirates and confirmed using standard assays. Optimal concentrations of Lithium chloride and SB216763 were determined based on the yield of viable cell numbers in MSC cultures treated with varying concentrations of either Lithium chloride or SB216763. Passaged-3 MSCs were then centrifuged into small aggregates and provided with a chondrogenic medium supplemented with either lithium or SB216763 reagent at the optimal concentration determined in the previous experiment. Three weeks after, GAG contents of the culture were quantified and compared to each other and the control. According to our data, the cultures treated with 5 mM Lithium and 1 µM SB216763 tended to have comparatively more viable cells; therefore these concentrations were used in the differentiation experiments. The addition of either SB216763 or lithium to chondrogenic cultures appeared to significantly enhance cartilage matrix production. In SB216763 and Lithium-treated cultures average GAG concentrations were 6.17 ± 0.7 and 6.12 ± 1.1 µg/ml compared to 2.00 ± 0.3 µg/ml in the control (p<0.05). Using SB216763 and Lithium as supplements in human marrow MSC chondrogenic culture can lead to the production of cartilage mass high in GAG content.
Full-text available
Received: 3/Sep/2008, Accepted: 29/Oct/2008 Objective: This study is an attempt to examine the anti apoptotic effects of BIO on rat MSC culture. Materials and Methods: Rat marrow primary cell culture was established and expo-sure groups were defined; cultures with 0.01, 0.1, 1 μM BIO. Cells cultured without BIO treatment were used as controls. During culture expantion, the average doubling time, as an index of the rate of cell growth, were determined and compared. To examine whether or not BIO is able to protect MSCs against apoptosis, the passaged-3 cells from each group were induced to undergo apoptosis with the addition of TNF-α (Tumor necrotic factor-α). Three days after, the cultures were quantified in terms of the percent-ages of apoptotic cells using either the Tunnel or Annexin V staining method. Results: Marrow cells cultivated with 0.1 and 1 μM BIO appeared to expand at a sig-nificantly more rapid rate than the 0.01 μM BIO and the control cultures (p<0.05). Tun-nel staining indicated that in 1 μM BIO-treated groups, there were lower percentages of apoptotic nuclei than in groups with other concentrations of BIO (p<0.05). The BIO protective effect appeared to be dose-dependent in that the cultures with high BIO con-tent possessed less apoptotic nuclei. The results obtained by Annexin staining were in agreement with the results of Tunnel staining. The Annexin method additionally takes into account the early apoptotic cells which are not detectable by the Tunnel method. Conclusion: Taken together, it seems that cultivation with BIO could both increase the growth rate of marrow cells and protect MSCs against induced apoptosis.
The surface of nucleosomes is studded with a multiplicity of modifications. At least eight different classes have been characterized to date and many different sites have been identified for each class. Operationally, modifications function either by disrupting chromatin contacts or by affecting the recruitment of nonhistone proteins to chromatin. Their presence on histones can dictate the higher-order chromatin structure in which DNA is packaged and can orchestrate the ordered recruitment of enzyme complexes to manipulate DNA. In this way, histone modifications have the potential to influence many fundamental biological processes, some of which may be epigenetically inherited.
Differentiation of stem cells from a pluripotent to a committed state involves global changes in genome expression patterns, the best known as "epigenetic modifications". Epigenetic mechanisms, including histone modifications, DNA methylation and non-coding RNA-mediated regulatory events are considered as the essential factors to control the heritable cellular memory of gene expression during development. With complete genome sequence in hand, understanding the epigenetic control of genome is the next step towards comprehending how the same DNA sequence gives rise to different cells and lineages, the phenomenon referred to as cell fate specification of stem cells. Here we discuss the epigenetic mechanisms which serve as the master regulators of cellular destiny through development.
Injuries to the articular cartilage are significant clinical problems due to cartilage's limited ability to regenerate itself. Despite the progress that's been made in orthopedic surgery and developing chondrocyte transplantation treatments and also in early tissue-engineering, cartilage regeneration using a biological approach still remains a great challenge. Mesenchymal stem cells (MSC) are multipotent cells that have the ability to differentiate into mesenchyme-derived cells, including chondrocytes. This review discusses the complexity and entailed challenges when using MSCs from various sources for clinical applications and the necessity to optimize chondrogenesis by repressing hypertrophy to obtain functional, suitable cells for repairing cartilage.